Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Unigene Laboratories Inc.
With
GlaxoSmithKline
The choice of a 24-week treatment period was based on published studies of PTH which demonstrate its potential to produce a statistically significant increase in BMD in patients with postmenopausal osteoporosis within that observation period.
Age
45–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Healthy postmenopausal women (45-80 years old) with a diagnosis of osteoporosis
You may not be if
Use of estrogen or hormone replacement therapy
Use of bisphosphonates, strontium ranelate or denosumab
Use of parathyroid analogues or other bone metabolic agents
Medical conditions which might alter bone metabolism
Any known clinically significant disease affecting calcium metabolism or history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia
